Diabetes Research & Innovations 🔬 - Happy Diabetes
Diabetes Research & Innovations 🔬
T1D Fundamentals
The essentials
An Essentials guide gets straight to the point: the key information on the topic, no detours. To go further, check out our full guides.
Explore the most exciting frontiers in Type 1 Diabetes research — from artificial pancreas systems already on the market to stem cell therapies, the first drug to delay T1D onset, and what's on the horizon. Learn what's approved, what's in trials, and how you can get involved.
1 learners
What this guide gives you
How hybrid closed-loop systems work — and what "fully closed loop" would mean
The history and current state of beta cell replacement
Teplizumab (Tzield): the first drug approved to delay T1D onset
Early-stage research: CRISPR and smart insulin
How to participate in research and advocate for a cure
Who is this for?
Newly diagnosedExperienced patients
The State of T1D Research — What's Real, What's Coming
Questions about this content?
Alfred can go deeper on any point in this section.
Want to go further?
Explore our full guides on this topic to deepen your knowledge.
Understand how current hybrid closed-loop systems work and how they differ from a "fully closed loop"
Know what teplizumab (Tzield) is and why its 2022 FDA approval was a historic milestone
Understand what beta cell replacement research involves and why it's challenging
Recognize the difference between approved therapies, clinical trials, and preclinical research
Know how to participate in or support T1D research
Section 1: Closed-Loop Systems — The Artificial Pancreas
Where We Are Today
The term "artificial pancreas" refers to a system that automatically adjusts insulin delivery based on continuous glucose monitoring (CGM) data — without you having to calculate doses manually every time.
Several hybrid closed-loop systems are already FDA-approved and commercially available:
System
Manufacturer
Status
Control-IQ
Tandem Diabetes Care
FDA approved, on market
CamAPS FX
CamDiab
CE-marked (Europe), available in UK & Europe
Omnipod 5
Insulet
FDA approved, on market
iLet Bionic Pancreas
Beta Bionics
FDA approved May 2023
These are called "hybrid" because they still require you to announce meals (bolus for food). The algorithm handles the background corrections, insulin suspensions, and micro-adjustments — but you still press a button for meals.
What "Fully Closed Loop" Would Mean
A fully closed loop — sometimes called a "no-bolus" system — would handle insulin delivery without any manual meal announcement. You would eat, and the system would detect the glucose rise and respond automatically.
Info
Fully closed-loop systems are actively being researched and have shown promise in clinical trials, but no fully automated commercial system is available for most patients yet. The iLet comes closest to this vision but still benefits from meal announcements.
Why It's Hard
The main challenge is the speed mismatch: glucose rises fast after a meal, but subcutaneous insulin takes 15–90 minutes to work. Even ultra-rapid insulins (Lyumjev, Fiasp) have limits. Future breakthroughs may involve:
Faster-acting insulin formulations
Dual-hormone systems (insulin + glucagon)
Predictive algorithms using heart rate, activity, or even food images
Quick Check: Artificial Pancreas Systems
1 / 3
Which of the following best describes a 'hybrid closed-loop' insulin delivery system?
Section 2: Beta Cell Replacement & Immunotherapy
Beta Cell Replacement: The Dream of Not Needing Insulin Injections
In T1D, the immune system destroys the beta cells in the pancreas — the only cells that produce insulin. The idea of replacing them has motivated researchers for decades.
The Edmonton Protocol (2000)
In 2000, researchers at the University of Alberta published a landmark study: they transplanted islet cells (clusters of beta cells) from deceased donors into people with T1D. Some patients achieved insulin independence for months to years. This was called the Edmonton Protocol.
The problem? Patients needed lifelong immunosuppressant drugs to prevent rejection — drugs with serious side effects. And donor pancreases are scarce.
Stem Cell-Derived Beta Cells: The Current Frontier
The most exciting development is the ability to grow insulin-producing cells from stem cells — potentially in unlimited quantities.
Vertex Pharmaceuticals (VX-880): In Phase 1/2 clinical trials published in 2023, Vertex reported that some patients achieved significant insulin reduction or full insulin independence after receiving stem cell-derived islet cells. These are early results in a small number of patients, but they represent a genuine proof of concept.
Info
Vertex VX-880 results are promising early-phase data — they demonstrate that stem cell-derived beta cells can survive and function in humans. However, these patients still require immunosuppression. The next frontier is eliminating that requirement.
Encapsulation: Avoiding Immunosuppression
One strategy to avoid immunosuppression is to encapsulate beta cells in a protective material that shields them from the immune system while allowing glucose and insulin to pass through. Multiple companies (including ViaCyte, now part of Vertex) are working on this.
This is still largely in preclinical and early clinical stages, but represents a potential path to transplantation without the risks of long-term immunosuppression.
Immunotherapy: Stopping T1D Before It Starts
Teplizumab (Tzield) — A Historic First
On November 17, 2022, the FDA approved teplizumab-mzwv (Tzield) — the first drug ever approved to delay the onset of Type 1 Diabetes.
Here's what makes this significant:
Tzield targets a specific immune protein (CD3 on T-cells) to slow the autoimmune attack on beta cells
In the TrialNet TN-10 trial, a single 14-day course of teplizumab delayed the progression to Stage 3 T1D (clinical diagnosis) by a median of approximately 3 years in people at high risk (Stage 2: two or more autoantibodies + abnormal glucose tolerance)
It does not cure T1D — it delays onset
It is indicated for people aged 8 and above who are at Stage 2 T1D (confirmed by testing)
Info
Tzield is a preventive treatment, not a cure. It works best when given before clinical T1D develops. This is why early screening (like TrialNet) is so important — you can't benefit from teplizumab if you don't know you're at risk.
How the mechanism works: T-cells are immune cells that play a key role in destroying beta cells in T1D. Teplizumab binds to CD3, a protein on T-cells, temporarily modulating their activity and creating a window in which the autoimmune attack slows down — buying time for remaining beta cells to survive.
Section 3: What's Coming Next & How to Stay Involved
CRISPR and Gene Editing
CRISPR-based approaches for T1D are generating scientific excitement. Researchers are exploring:
Editing immune cells to prevent beta cell destruction
Modifying stem cell-derived beta cells to make them "invisible" to the immune system (universal donor cells)
The honest picture: As of 2025, CRISPR for T1D is preclinical or very early-stage. No CRISPR therapy is currently approved or in late-stage trials for T1D. The science is promising but timelines are uncertain. We should celebrate the progress without overstating it.
Smart Insulin (Glucose-Responsive Insulin)
Smart insulin — also called glucose-activated insulin — is a theoretical formulation that would only activate when blood sugar is high, and become inactive when glucose is normal. It would be a major safety advance by making hypoglycemia much less likely.
Multiple academic labs and companies (including Novo Nordisk and Eli Lilly) are working on glucose-responsive insulin. As of 2025, this is still in research phase — no glucose-responsive insulin has been approved for human use. Early results in animal models are encouraging.
How You Can Get Involved
You don't have to wait for a cure to contribute to T1D research:
Participate in research:
TrialNet (trialnet.org): Free screening for relatives of people with T1D. Early detection enables access to preventive therapies like teplizumab.
JDRF T1D Exchange (jdrf.org): A registry connecting people with T1D to clinical trials.
Breakthrough T1D (breakthrought1d.org): Advocacy and research funding organization (formerly JDRF).
Stay informed:
Follow ADA conference announcements (June each year)
Check ClinicalTrials.gov for T1D studies
Subscribe to newsletters from TrialNet and Breakthrough T1D
Advocate:
Support policies that fund diabetes research
Share your story — patient voices influence research priorities and funding
Info
This guide is updated periodically as the research landscape evolves. Research advances quickly — check back for updates!
Key takeaways
Hybrid closed-loop systems (Control-IQ, Omnipod 5, CamAPS FX, iLet) are already on the market and significantly improve glycemic control — but they still require meal announcements; a truly autonomous "fully closed loop" is not yet commercially available
Teplizumab (Tzield), FDA-approved November 2022, is the first drug to delay T1D onset — it buys ~3 years in high-risk individuals at Stage 2 T1D
Stem cell-derived beta cell replacement (Vertex VX-880) has shown early proof of concept in clinical trials, but still requires immunosuppression — encapsulation strategies aim to solve this
CRISPR and smart insulin are promising but preclinical/early-stage — expect timelines of many years before clinical use
You can participate today: TrialNet screens at-risk relatives for free, enabling access to preventive therapies
Chapter Quiz: Diabetes Research & Innovations
1 / 5
Teplizumab (Tzield) was FDA-approved in November 2022. What does it do?
